===
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
02-Jul-2024 / 11:25 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Aubagne, July 2nd, 2024
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following
resources appeared on the liquidity account on June 30th 2024:
? 46,292 shares
? EUR 2,521,189.91
? Number of executions on buy side on semester: 6,493
? Number of executions on sell side on semester: 5,322
? Traded volume on buy side on semester: 305,402 shares for EUR 69,412,550.00
? Traded volume on sell side on semester: 273,281 shares for EUR 63,664,027.43
As a reminder :
The following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:
? 14,171 shares
? EUR 8,132,662.14
? Number of executions on buy side on semester: 5,238
? Number of executions on sell side on semester: 4,912
? Traded volume on buy side on semester: 230,377 shares for EUR 50,832,014.40
? Traded volume on sell side on semester: 239,123 shares for EUR 54,101,099.12
The following resources appeared on the liquidity account when the activity started:
? 0 shares
? EUR 10,000,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing
the implementation of liquidity contracts for shares as an accepted market practice.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are
quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros.
Currently, more than 10,600 employees are working for customers around the globe.
Contact
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
Petra.mueller2@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius.com
Buy side Sell side
Number of Number of Traded volume in Number of Number of Traded volume in
executions shares EUR executions shares EUR
Total 6,493 305,402 69,412,550.00 5,322 273,281 63,664,027.43
01/02/2024 16 1,000 244,350.00 107 4,495 1,109,725.60
01/03/2024 82 3,428 839,277.24 28 1,600 393,104.00
01/04/2024 91 3,592 864,342.96 41 1,662 404,397.84
01/05/2024 103 3,499 818,731.01 54 2,800 660,492.00
01/08/2024 92 3,350 786,881.50 47 2,500 590,150.00
01/09/2024 33 1,700 403,546.00 36 2,300 550,390.00
01/10/2024 85 3,800 912,152.00 44 1,901 460,346.16
01/11/2024 74 3,350 793,816.00 50 2,601 620,234.46
01/12/2024 65 3,500 821,065.00 59 2,600 616,070.00
01/15/2024 54 1,900 440,952.00 31 1,611 374,879.70
01/16/2024 165 4,500 1,004,760.00 32 1,900 427,994.00
01/17/2024 62 2,700 600,723.00 41 1,400 313,026.00
01/18/2024 54 2,400 533,784.00 37 1,800 403,704.00
01/19/2024 35 1,991 433,878.72 47 2,600 570,908.00
01/22/2024 41 1,700 378,658.00 63 2,500 559,900.00
01/23/2024 55 2,540 565,683.40 46 2,225 497,376.50
01/24/2024 71 3,300 740,487.00 72 3,176 716,473.84
01/25/2024 48 2,470 551,872.10 86 4,009 903,548.42
01/26/2024 54 2,605 614,884.20 125 6,725 1,618,976.50
01/29/2024 65 3,303 788,591.25 47 2,826 680,755.14
01/30/2024 108 5,073 1,186,879.08 83 4,604 1,103,716.92
01/31/2024 - - - 84 4,599 1,135,171.17
02/01/2024 58 2,675 663,186.00 29 1,423 354,711.21
02/02/2024 85 4,200 1,036,182.00 55 1,777 444,392.16
02/05/2024 43 1,700 411,400.00 55 3,002 732,217.82
02/06/2024 44 2,140 525,669.60 50 2,500 619,550.00
02/07/2024 91 4,300 1,051,436.00 56 3,500 880,390.00
02/08/2024 83 3,700 947,681.00 96 4,500 1,172,115.00
02/09/2024 67 3,700 930,624.00 71 3,700 936,729.00
02/12/2024 79 4,101 1,015,899.72 29 1,600 401,152.00
02/13/2024 77 3,821 921,816.25 29 1,600 388,464.00
02/14/2024 54 2,247 536,740.89 46 2,509 601,733.47
02/15/2024 40 1,860 449,692.20 68 2,891 702,137.17
02/16/2024 13 500 123,700.00 84 4,400 1,098,900.00
02/19/2024 41 2,313 579,221.46 60 3,000 757,890.00
02/20/2024 56 2,987 750,722.71 8 403 102,108.11
02/21/2024 82 4,100 1,010,937.00 35 1,700 426,955.00
02/22/2024 25 1,102 279,059.46 79 3,812 969,505.96
02/23/2024 55 2,448 612,979.20 21 900 225,846.00
02/26/2024 60 3,098 767,033.82 13 900 225,099.00
02/27/2024 34 2,200 543,840.00 45 2,700 670,707.00
02/28/2024 18 1,217 303,483.29 39 2,200 550,880.00
02/29/2024 21 1,024 259,307.52 85 3,585 912,633.45
03/01/2024 62 3,859 965,598.98 29 1,800 454,140.00
03/04/2024 41 2,200 551,694.00 29 1,500 377,325.00
03/05/2024 40 2,000 498,900.00 52 2,700 677,403.00
Buy side Sell side
Number of Number of Traded volume in Number of Number of Traded volume in
executions shares EUR executions shares EUR
Total 6,493 305,402 69,412,550.00 5,322 273,281 63,664,027.43
03/06/2024 17 955 241,777.35 67 3,800 967,784.00
03/07/2024 7 512 132,469.76 88 4,400 1,152,800.00
03/08/2024 - - - 50 2,400 645,912.00
03/11/2024 70 3,152 847,856.48 59 2,700 730,269.00
03/12/2024 38 1,950 528,430.50 57 2,800 764,092.00
03/13/2024 66 3,400 922,794.00 36 2,159 590,054.70
03/14/2024 23 1,800 496,152.00 74 3,442 951,850.68
03/15/2024 80 4,440 1,217,670.00 32 1,904 524,456.80
03/18/2024 88 3,908 1,053,557.72 14 900 246,447.00
03/19/2024 55 2,351 617,983.86 45 2,300 607,016.00
===
(MORE TO FOLLOW) Dow Jones Newswires
July 02, 2024 05:27 ET (09:27 GMT)